ME/CFS Adaptive Therapeutic Solution Platform (MEDUSA) – Phase 1
The purpose of phase 1 of this study is to identify promising treatments for specific subgroups of people with ME/CFS, which will be evaluated in later phases.
Multi-Omic Approaches to Solve Post-Acute COVID-19 (MOSAIC)

The purpose of this study is to facilitate early detection of ME/CFS in people with Long COVID and better understand disease progression.
RAman SPectrometry Based biomarkER discoveRY for Myalgic Encephalomyelitis (RASPBERRY-ME)

The overarching goal of RASPBERRY-ME project is the characterization of the biomolecular signature of Myalgic Encephalomyelitis using Label-free Raman Spectroscopy (RS) and machine learning models.
Precision Medicine for Myalgic Encephalomyelitis Drug Discovery and ClinicaI Trials (REMEDIAL)
The REMEDIAL project continues the work commenced with MAESTRO and will lead to a better understanding of the molecular mechanisms underlying ME/CFS pathophysiology,
the persistence and variability of the symptoms, and will contribute to the identification of targets and therapeutic agents for intervention.
Deep Proteome and Metabolome Profiling
Decode the molecular mechanisms underlying ME/CFS and contributing to specific symptoms with a particular emphasis of post-exertional malaise (PEM). This includes deep phenotyping of ME patients and global proteomic/metabolomics plasma profiling of ME..